Introduction {#jde14218-sec-0001}
============

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by xerosis, intense pruritus and eczematous lesions. Patients with AD experience a fluctuating course of flares and spontaneous apparent remission.[1](#jde14218-bib-0001){ref-type="ref"}, [2](#jde14218-bib-0002){ref-type="ref"} In most cases, AD presents in early infancy or childhood and often resolves by puberty. However, in approximately 50% of cases, it extends into adult life, evolving into a chronic lifelong condition.[2](#jde14218-bib-0002){ref-type="ref"}, [3](#jde14218-bib-0003){ref-type="ref"}, [4](#jde14218-bib-0004){ref-type="ref"} In addition, it is increasingly being recognized that AD can present for the first time in adults as adult‐onset AD.[5](#jde14218-bib-0005){ref-type="ref"}, [6](#jde14218-bib-0006){ref-type="ref"}, [7](#jde14218-bib-0007){ref-type="ref"}

Atopic dermatitis is the most common inflammatory skin disease, with a 1‐year prevalence in US adults of 10.2%.[8](#jde14218-bib-0008){ref-type="ref"} By comparison, in Japanese adults, the point prevalence of AD (2004) was estimated at 6.9%,[9](#jde14218-bib-0009){ref-type="ref"} presenting in a mild form in 76.7% of patients, as moderate disease in 18.5% of cases and as severe or very severe disease in 4.8% of patients.[9](#jde14218-bib-0009){ref-type="ref"}

Skin diseases are among the leading causes of non‐fatal disease burden worldwide, as demonstrated by the Global Burden of Diseases Study.[10](#jde14218-bib-0010){ref-type="ref"} Accordingly, characterizing the burden of disease in patients with AD is crucial in promoting evidence‐based allocation of health‐care resources and highlighting AD as a global health problem. The multidimensional burden of disease in North American and European AD patients is well documented. Relative to the general population, patients with AD experience increased levels of itch, pain, sleep disturbance, anxiety and depression, as well as an impaired health‐related quality of life (HRQoL).[11](#jde14218-bib-0011){ref-type="ref"}, [12](#jde14218-bib-0012){ref-type="ref"}, [13](#jde14218-bib-0013){ref-type="ref"}, [14](#jde14218-bib-0014){ref-type="ref"}, [15](#jde14218-bib-0015){ref-type="ref"} In contrast, published data on the burden of AD in the Japanese patient population is limited to two relatively small studies.[16](#jde14218-bib-0016){ref-type="ref"}, [17](#jde14218-bib-0017){ref-type="ref"}

With this in mind, the objective of the present study was to perform a comprehensive characterization of the real‐world burden of AD in Japanese adult patients, encompassing comorbidities, mood and sleep disorders, HRQoL, work productivity, activity and health‐care resource utilization (HCRU), based on data from the 2013 National Health and Wellness Survey (NHWS).[18](#jde14218-bib-0018){ref-type="ref"} The study also aimed to evaluate the impact of patient‐rated AD severity on the burden of AD in Japanese adult patients.

Methods {#jde14218-sec-0002}
=======

Data source {#jde14218-sec-0003}
-----------

Patient data were obtained from the 2013 Japan NHWS, an Internet‐based, international population survey conducted in Japan, the USA, China, Russia, Brazil and Europe.[18](#jde14218-bib-0018){ref-type="ref"} The Japanese NHWS uses a random, stratified sampling framework, including sex and age, to ensure that it is representative of the demographic composition of the Japanese adult population, based on data from the Japan population census.[19](#jde14218-bib-0019){ref-type="ref"} A total of 607 712 individuals were asked to complete the 2013 Japanese NHWS, of whom 41 893 responded (6.9%). Of the responders, 30 000 (71.6%) met the inclusion criteria (Japanese adults, age ≥18 years, who can read and write Japanese), completed the survey and gave informed consent for their anonymized data to be used for research purposes. The NHWS was approved by the Essex Institutional Review Board (Lebanon, NJ, USA).[15](#jde14218-bib-0015){ref-type="ref"}

Analysis cohort {#jde14218-sec-0004}
---------------

The AD cohort comprised adult respondents who indicated that they had experienced AD in response to the question: "Which of the following conditions have you experienced in the past 12 months?". Possible response options were: select all that apply/I have not experienced any of the above conditions in the past 12 months/decline to answer. To be included in the analysis, respondents also had to answer "yes" to the NHWS question: "Has your AD been diagnosed by a physician?". The non‐AD control cohort comprised adult respondents who did not report experiencing AD, dermatitis or eczema in the past 12 months. Adults with AD graded their disease severity as "mild", "moderate" or "severe" in response to the NHWS question, "How severe is your dermatitis/eczema?".

Propensity‐score matching {#jde14218-sec-0005}
-------------------------

To correct for potential confounding, AD patients were propensity‐score matched[20](#jde14218-bib-0020){ref-type="ref"} to non‐AD controls in a 1:2 ratio. Matching of AD patients and non‐AD controls was based on the demographic variables age, sex, marital status, education, income, insurance status, body mass index, smoking status and the Charlson comorbidity index (CCI).[21](#jde14218-bib-0021){ref-type="ref"} The CCI is a weighted index that predicts the 1‐year mortality of patients based on the presence of a total of 19 comorbid conditions. In the NHWS, hemiplegia and moderate/severe liver disease are not included; thus, data is collected for 17 comorbid conditions. Each condition is assigned a score of 1, 2, 3 or 6, with higher scores indicating a higher risk of mortality. Scores are summed to provide an overall measure of comorbidity and risk of mortality. Variables were entered into a logistic regression model using the SAS/STAT^®^ LOGISTIC procedure to generate the propensity score. Matching was completed using the "greedy matching" technique.[22](#jde14218-bib-0022){ref-type="ref"} The algorithm creates the "best" matches first and the "next‐best" matches next, in a hierarchical sequence, until no more matches can be made. Best matches are those with the highest digit match on propensity score. Matched pairs were defined as those with the lowest difference in propensity score.

Comorbidities {#jde14218-sec-0006}
-------------

Self‐reported diagnoses of arthritis (including osteoarthritis, rheumatoid arthritis and psoriatic arthritis), atopic‐related comorbidities (asthma, hay fever/nasal allergies), diabetes, hypertension, high cholesterol and osteoporosis/osteopenia were based on respondents' answers to the questions: "Which of the following conditions have you experienced in the past 12 months?" or "Which of the following conditions have you ever experienced". In addition, respondents had to answer "yes" to the question, "Has your condition been diagnosed by a physician?".

Mental health {#jde14218-sec-0007}
-------------

Self‐reported diagnoses of anxiety, depression and/or sleep disorders were based on responses to the questions: "Have you experienced anxiety/depression/sleep disorder (separate question for each disorder) in the past 12 months?". Additionally, respondents had to answer "yes" to the question, "Has your anxiety/depression/sleep disorder been diagnosed by a physician?" (separate question for each disorder).

Outcomes {#jde14218-sec-0008}
--------

### Health‐related quality of life {#jde14218-sec-0009}

Health‐related quality of life during the past 4 weeks was assessed with the Japanese version[23](#jde14218-bib-0023){ref-type="ref"} of the 36‐item Short Form Health Survey (SF‐36v2) Mental Component Summary (MCS) and Physical Component Summary (PCS) scores, normed to a mean of 50 (standard deviation \[SD\] of 10) based on the US population, with higher scores indicating better health.[24](#jde14218-bib-0024){ref-type="ref"}, [25](#jde14218-bib-0025){ref-type="ref"} In addition, the Short Form 6‐Dimension (SF‐6D) utility score was calculated, a preference‐based single index measure for health based on SF‐36 data, weighted according to general population values for health, with a hypothetical range of 0--1.0, where 1.0 indicates "full health".[26](#jde14218-bib-0026){ref-type="ref"}

### Work productivity and activity impairment {#jde14218-sec-0010}

The Japanese version[16](#jde14218-bib-0016){ref-type="ref"} of the work productivity and activity impairment questionnaire[27](#jde14218-bib-0027){ref-type="ref"} evaluated respondents in full‐time or part‐time employment across four domains: absenteeism (percentage of work time missed during the past 7 days due to the health problem); presenteeism (percentage of work time impaired due to the health problem during the past 7 days); overall work impairment (percentage of total work impairment due to the health problem \[absenteeism + presenteeism\]); and activity impairment (percentage of activity impairment due to the health problem).

### Health‐care resource utilization {#jde14218-sec-0011}

Health‐care resource utilization (HCRU) in the past 6 months was evaluated based on responses to the following survey questions: "How many visits did you make to the following traditional health‐care provider(s) (e.g. general/family practitioner, internist, cardiologist, allergist, dermatologist) in the past 6 months?", "How many times have you been to the emergency room (ER) for your own medical condition in the past 6 months?" and "How many times have you been hospitalized for your own medical condition in the past 6 months?".

Statistical methods {#jde14218-sec-0012}
-------------------

Bivariate analyses of variables were conducted for AD patients versus matched non‐AD controls, and moderate/severe AD versus mild AD groups. Pearson\'s χ^2^‐test or Student\'s *t*‐test were used to compare differences between groups for categorical or continuous variables, respectively. Analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).

Results {#jde14218-sec-0013}
=======

Analysis cohort {#jde14218-sec-0014}
---------------

The AD cohort contained 638 Japanese adult patients with AD, of whom 290 (45.45%) rated their disease as moderate/severe and 348 (54.54%) as mild (Table [1](#jde14218-tbl-0001){ref-type="table-wrap"}). Four AD patients could not be matched with non‐AD control subjects and were removed from the analysis. Therefore, a total of 1902 adults were included in the matched analysis cohort, comprising 634 AD patients and 1268 non‐AD controls (1:2 ratio). The mean (SD) age of the analysis cohort was 38.51 (12.92) years and approximately half were female (50.16%). Demographic characteristics were similar between AD patients and matched non‐AD controls (Table [1](#jde14218-tbl-0001){ref-type="table-wrap"}), confirming that propensity‐score matching had been effective in matching AD patients to non‐AD controls. Demographic characteristics were also generally similar between moderate/severe and mild AD patients, but some significant differences were identified. A significantly lower proportion of moderate/severe AD patients reported being married or living with a partner compared with mild AD patients (37.24% vs 49.14%, respectively; *P* = 0.003). Annual household income also tended to be lower among patients with moderate/severe AD, with 18.62% of these patients reporting an annual income of at least ¥8 million compared with 25.86% of mild AD patients (*P* = 0.024) (Table [1](#jde14218-tbl-0001){ref-type="table-wrap"}). In addition, a lower proportion of patients with moderate/severe AD reported smoking compared with mild AD patients (19.66% vs 23.56%; *P* = 0.016).

###### 

Demographic characteristics in the matched analysis cohort of AD patients and non‐AD controls and in AD patients according to self‐rated disease severity

                                                   Total (*n* = 1902)   AD (*n* = 634)[†](#jde14218-note-0001){ref-type="fn"}   Non‐AD (*n* = 1268)   *P*     Moderate/severe AD (*n* = 290)[†](#jde14218-note-0001){ref-type="fn"}   Mild AD (*n* = 348)[†](#jde14218-note-0001){ref-type="fn"}   *P*
  ------------------------------------------------ -------------------- ------------------------------------------------------- --------------------- ------- ----------------------------------------------------------------------- ------------------------------------------------------------ -------
  Age, years, mean (SD)                            38.51 (12.92)        38.67 (13.07)                                           38.43 (12.85)         0.695   37.53 (12.81)                                                           39.51 (13.21)                                                0.056
  Female, *n* (%)                                  954 (50.16)          332 (52.37)                                             622 (49.05)           0.173   148 (51.03)                                                             186 (53.45)                                                  0.543
  Married/living with partner, *n* (%)             833 (43.80)          277 (43.69)                                             556 (43.85)           0.948   108 (37.24)                                                             171 (49.14)                                                  0.003
  College educated, *n* (%)                        1040 (54.68)         338 (53.31)                                             702 (55.36)           0.397   146 (50.34)                                                             195 (56.03)                                                  0.151
  Annual household income ≥¥8 million, ‡ *n* (%)   400 (21.03)          140 (22.08)                                             260 (20.50)           0.929   54 (18.62)                                                              90 (25.86)                                                   0.024
  Employed full time, *n* (%)                      864 (45.43)          279 (44.01)                                             585 (46.14)           0.379   127 (43.79)                                                             155 (44.54)                                                  0.850
  Student, *n* (%)                                 132 (6.94)           52 (8.20)                                               80 (6.31)             0.126   31 (10.69)                                                              22 (6.32)                                                    0.047
  Body mass index, mean (SD)                       21.84 (3.77)         21.81 (3.69)                                            21.86 (3.81)          0.805   21.79 (4.11)                                                            21.83 (3.33)                                                 0.880
  Alcohol use, *n* (%)                             1286 (67.61)         434 (68.45)                                             852 (67.19)           0.579   195 (67.24)                                                             243 (69.83)                                                  0.483
  Current smoker, *n* (%)                          427 (22.45)          135 (21.29)                                             292 (23.03)           0.381   57 (19.66)                                                              82 (23.56)                                                   0.016
  Taking regular exercise, *n* (%)                 777 (40.85)          274 (43.22)                                             503 (39.67)           0.138   120 (41.38)                                                             158 (45.40)                                                  0.308
  Charlson comorbidity index, mean (SD)            0.17 (0.60)          0.18 (0.59)                                             0.16 (0.60)           0.499   0.34 (2.80)                                                             0.34 (1.87)                                                  0.970

†Of the 638 AD patients who met the inclusion criteria, four were not able to be matched to non‐AD controls. As of July 2017, ¥8 million was equivalent to approximately \$US70 000. AD, atopic dermatitis; SD, standard deviation.

John Wiley & Sons, Ltd

Comorbidities {#jde14218-sec-0015}
-------------

Significantly higher self‐reported prevalences of arthritis (3.79% vs 0.87%), asthma (12.62% vs 2.44%) and nasal allergies/hay fever (36.91% vs 14.83%) were observed in AD patients compared with matched non‐AD controls (all *P* \< 0.001; Table [2](#jde14218-tbl-0002){ref-type="table-wrap"}). Additionally, the self‐reported prevalences of high cholesterol (8.99% vs 4.26%; *P* \< 0.001) and osteoporosis/osteopenia (1.42% vs 0.47%; *P* \< 0.028) were also significantly higher in AD patients compared with non‐AD controls. No statistically significant differences were reported for diabetes and hypertension. In addition, there were no significant differences in the self‐reported prevalence of any of the evaluated comorbidities between moderate/severe and mild AD patients (Table [2](#jde14218-tbl-0002){ref-type="table-wrap"}).

###### 

Self‐reported prevalence of comorbid conditions in AD patients versus matched non‐AD controls and moderate/severe versus mild AD patients

  Comorbidity, n (%)                                  AD (*n* = 634)   Non‐AD (*n* = 1268)   *P*       Moderate/severe AD (*n* = 290)   Mild AD (*n* = 348)   *P*
  --------------------------------------------------- ---------------- --------------------- --------- -------------------------------- --------------------- -------
  Diabetes                                            17 (2.68)        34 (2.68)             1         8 (2.76)                         12 (3.45)             0.619
  Hypertension                                        47 (7.41)        72 (5.68)             0.141     18 (6.21)                        32 (9.20)             0.162
  High cholesterol                                    57 (8.99)        54 (4.26)             \<0.001   22 (7.59)                        38 (10.92)            0.151
  Osteoporosis/osteopenia                             9 (1.42)         6 (0.47)              0.028     4 (1.38)                         9 (2.59)              0.283
  Arthritis (osteoarthritis, rheumatoid, psoriatic)   24 (3.79)        11 (0.87)             \<0.001   11 (3.79)                        17 (4.89)             0.503
  Asthma                                              80 (12.62)       31 (2.44)             \<0.001   34 (11.72)                       50 (14.37)            0.325
  Nasal allergies/hay fever                           234 (36.91)      188 (14.83)           \<0.001   107 (36.90)                      131 (37.64)           0.846

AD, atopic dermatitis.

John Wiley & Sons, Ltd

Mood and sleep disorders {#jde14218-sec-0016}
------------------------

The self‐reported prevalences of depression (10.25% vs 4.26%), anxiety (3.31% vs 1.03%) and sleep disorders (12.93% vs 4.57%) were all significantly greater in AD patients compared with matched non‐AD controls (all *P* \< 0.001; Fig. [1](#jde14218-fig-0001){ref-type="fig"}a). No significant differences were observed in the self‐reported prevalence of mood or sleep disorders between moderate/severe and mild AD patients (Fig. [1](#jde14218-fig-0001){ref-type="fig"}b).

![Self‐reported prevalence of mood and sleep disorders in (a) atopic dermatitis (AD) patients versus matched non‐AD controls and (b) moderate/severe versus mild AD patients.](JDE-45-390-g001){#jde14218-fig-0001}

Health‐related quality of life {#jde14218-sec-0017}
------------------------------

Table [3](#jde14218-tbl-0003){ref-type="table-wrap"} shows that AD patients reported significantly reduced HRQoL relative to matched non‐AD controls, with regards to both mental (SF‐36v2 MCS) and physical (SF‐36v2 PCS) domains, as well as overall health (SF‐6D utility). Mean MCS, PCS and SF‐6D scores were numerically lower for moderate/severe AD patients compared with mild AD patients; however, the differences did not reach statistical significance (Table [3](#jde14218-tbl-0003){ref-type="table-wrap"}).

###### 

Health‐related quality of life in AD patients versus matched non‐AD controls and moderate/severe versus mild AD patients

  Score, mean (SD)   AD (*n* = 634)   Non‐AD (*n* = 1268)   *P*       Moderate/severe AD (*n* = 290)   Mild AD (*n* = 348)   *P*
  ------------------ ---------------- --------------------- --------- -------------------------------- --------------------- -------
  SF‐36 MCS          42.29 (11.49)    46.05 (9.92)          \<0.001   41.42 (11.78)                    42.82 (11.31)         0.127
  SF‐36 PCS          52.04 (6.81)     54.12 (6.07)          \<0.001   51.66 (6.92)                     52.29 (6.75)          0.246
  SF‐6D utility      0.71 (0.13)      0.76 (0.13)           \<0.001   0.69 (0.13)                      0.71 (0.13)           0.059

AD, atopic dermatitis; MCS, mental component summary, PCS, physical component summary; SF‐36, 36‐item Short Form Health Survey; SF‐6D, Short Form 6‐Dimension.

John Wiley & Sons, Ltd

Work productivity and activity {#jde14218-sec-0018}
------------------------------

Table [4](#jde14218-tbl-0004){ref-type="table-wrap"} shows that employed AD patients reported significantly higher presenteeism than matched non‐AD controls (28.63% vs 22.37%; *P* \< 0.001) but there was no statistically significant difference in absenteeism between the two groups. This translated into significantly higher overall work impairment in employed AD patients relative to employed non‐AD controls (30.61% vs 24.62%; *P* \< 0.001). Activity was also significantly impaired in AD patients compared with non‐AD controls (32.18% vs 24.72%; *P* \< 0.001). This data pattern was replicated in the analyses according to self‐rated disease severity. Patients with moderate/severe AD reported significantly higher presenteeism (32.17% vs 26.10%; *P* = 0.018), overall work impairment (33.79% vs 28.08%; *P* = 0.040) and activity impairment (35.14% vs 30.06%; *P* = 0.023) compared with patients with mild AD (Table [4](#jde14218-tbl-0004){ref-type="table-wrap"}).

###### 

Work productivity and activity impairment in AD patients versus matched non‐AD controls and moderate/severe versus mild AD patients

  Impairment in the last 7 days, mean (SD)[a](#jde14218-note-0004){ref-type="fn"}   AD (*n* = 634)   Non‐AD (*n* = 1268)   *P*       Moderate/severe AD (*n* = 290)   Mild AD (*n* = 348)   *P*
  --------------------------------------------------------------------------------- ---------------- --------------------- --------- -------------------------------- --------------------- -------
  Absenteeism                                                                       4.01 (12.32)     3.54 (13.78)          0.565     3.82 (10.39)                     4.33 (13.95)          0.689
  Unemployed/missing data, *n*                                                      248              447                             112                              138                   
  Presenteeism                                                                      28.63 (25.33)    22.37 (24.91)         \<0.001   32.17 (24.86)                    26.10 (25.92)         0.018
  Unemployed/missing data, *n*                                                      239              427                             110                              130                   
  Overall work impairment                                                           30.61 (27.17)    24.62 (27.16)         \<0.001   33.79 (26.26)                    28.08 (28.00)         0.040
  Unemployed/missing data, *n*                                                      248              447                             112                              138                   
  Activity impairment                                                               32.18 (27.93)    24.72 (26.62)         \<0.001   35.14 (27.58)                    30.06 (28.35)         0.023

The percentage of time missed from work/daily activity. AD, atopic dermatitis; SD, standard deviation.

John Wiley & Sons, Ltd

Health‐care resource utilization {#jde14218-sec-0019}
--------------------------------

As shown in Table [5](#jde14218-tbl-0005){ref-type="table-wrap"}, patients with AD reported significantly greater mean (SD) numbers of visits to a health‐care provider in the past 6 months compared with non‐AD controls (8.06 \[16.90\] vs 3.05 \[6.27\]; *P* \< 0.001). Although ER visits also showed a significant difference (0.26 \[1.86\] vs 0.07 \[0.53\]; *P* \< 0.001), the overall number of ER visits was very low, suggesting that Japanese AD patients do not usually visit the ER. There were no significant differences in HCRU between moderate/severe and mild AD patients (Table [5](#jde14218-tbl-0005){ref-type="table-wrap"}).

###### 

Health‐care resource utilization in AD patients versus matched non‐AD controls and moderate/severe versus mild AD patients

  HCRU in the past 6 months, mean (SD)   AD (*n* = 634)   Non‐AD (*n* = 1268)   *P*       Moderate/severe AD (*n* = 290)   Mild AD (*n* = 348)   *P*
  -------------------------------------- ---------------- --------------------- --------- -------------------------------- --------------------- -------
  Health‐care provider visits            8.06 (16.90)     3.05 (6.27)           \<0.001   10.08 (25.97)                    8.06 (20.81)          0.275
  Hospitalizations                       0.59 (3.42)      0.39 (4.20)           0.313     0.57 (3.10)                      0.72 (4.00)           0.611
  Emergency room visits                  0.26 (1.86)      0.07 (0.53)           \<0.001   0.24 (1.47)                      0.33 (2.23)           0.588

AD, atopic dermatitis; HCRU, health‐care resource utilization; SD, standard deviation.

John Wiley & Sons, Ltd

Discussion {#jde14218-sec-0020}
==========

In this population‐based survey study, we sought to provide a comprehensive evaluation of the patient‐reported burden of AD in the Japanese adult population. Japanese adult patients with AD reported a higher prevalence of arthritis, as well as the atopic comorbidities asthma and nasal allergies/hay fever relative to matched non‐AD controls. The association between AD and other atopic conditions has been recognized in previous studies,[6](#jde14218-bib-0006){ref-type="ref"}, [28](#jde14218-bib-0028){ref-type="ref"}, [29](#jde14218-bib-0029){ref-type="ref"} and is consistent with the concept of the "atopic march", which postulates that AD predicts the development of other common allergic conditions.[30](#jde14218-bib-0030){ref-type="ref"}

Rates of self‐reported depression, anxiety and sleep disorders were also significantly higher in patients with AD relative to non‐AD controls, corroborating the psychological impact of AD observed in previous studies of European[11](#jde14218-bib-0011){ref-type="ref"} and Japanese[17](#jde14218-bib-0017){ref-type="ref"} AD patients. It is to be noted that these comorbidities may be in addition to other comorbidities of AD which have been recently identified. For example, a German retrospective cohort study demonstrated that patients with AD were at increased risk for incident rheumatoid arthritis (risk ratio, 1.72; 95% confidence interval \[CI\], 1.25--2.37) with no disproportionate occurrence of known genetic risk alleles.[31](#jde14218-bib-0031){ref-type="ref"} A similar observation was reported in a study conducted in Taiwan, with a significant association between rheumatoid arthritis and atopy (hazard ratio, 1.74; 95% CI, 1.31--2.33).[32](#jde14218-bib-0032){ref-type="ref"} These results suggest that the link between AD and rheumatoid arthritis appears in different races. The present Japanese data also suggest a similar trend; however, owing to the limited numbers of participants, further investigations are warranted to establish and explain the mechanism underlying the observed correlations.[33](#jde14218-bib-0033){ref-type="ref"} A Taiwanese cohort study also demonstrated a link between AD and osteoporosis, compared with a non‐AD cohort.[34](#jde14218-bib-0034){ref-type="ref"} We believe the present background‐matched study may add another line of evidence of particular comorbidities in patients with AD.

Atopic dermatitis patients also reported significantly reduced HRQoL relative to non‐AD controls, with regards to both mental (MCS) and physical (PCS) domains and overall utility score. The mean MCS score in AD patients (42.29) was substantially less than the norm of 50, consistent with the self‐reported prevalence of depression, anxiety and sleep disorders in AD patients. A salient question is whether the observed differences in MCS and PCS scores between AD patients and controls are clinically meaningful. Previous studies of several chronic health conditions have cited SF‐36 score changes of 3--5 points as clinically meaningful,[35](#jde14218-bib-0035){ref-type="ref"}, [36](#jde14218-bib-0036){ref-type="ref"}, [37](#jde14218-bib-0037){ref-type="ref"}, [38](#jde14218-bib-0038){ref-type="ref"}, [39](#jde14218-bib-0039){ref-type="ref"} suggesting that the 4‐point reduction in mean MCS score between the AD and control groups observed in the current study is clinically significant. However, it should be noted that the minimal clinically important difference for MCS and PCS have yet to be defined for AD. Nevertheless, the self‐reported psychological burden of AD combined with the impact on HRQoL demonstrated in this study suggest the need for improved management of AD in order to improve the general well‐being and quality of life of patients with AD.[40](#jde14218-bib-0040){ref-type="ref"}, [41](#jde14218-bib-0041){ref-type="ref"}

In line with previous studies of Japanese patients with AD,[16](#jde14218-bib-0016){ref-type="ref"}, [37](#jde14218-bib-0037){ref-type="ref"} both work productivity and activity were negatively affected by AD. Overall, Japanese workers with AD reported 30.61% work impairment, very similar to the 30% figure reported in the US NHWS AD study.[15](#jde14218-bib-0015){ref-type="ref"} Of interest, employed Japanese AD patients reported significantly higher presenteeism, but not absenteeism, compared with employed non‐AD controls. This is an important finding as it has been estimated that the cost of presenteeism to the US economy is 10‐times higher than that of absenteeism, amounting to \$US1500 billion per year.[42](#jde14218-bib-0042){ref-type="ref"} In contrast, in the US NHWS study, both presenteeism and absenteeism were significantly greater in AD patients than in non‐AD controls.[15](#jde14218-bib-0015){ref-type="ref"} The contrasting work productivity data in the two NHWS studies may reflect cultural differences in attitudes towards absence from work in Japan and the USA.

In accordance with the high comorbidity and psychological burden associated with AD, HCRU was significantly higher in patients with AD compared with non‐AD controls. Similar findings were seen in the US NHWS study, where units of resource use, including health‐care practitioner, ER and hospital visits, were also significantly higher for patients with AD relative to non‐AD controls.[15](#jde14218-bib-0015){ref-type="ref"} In the current study, health‐care provider visits were the main driver behind the increased HCRU in patients with AD.

Self‐rated disease severity did not demonstrate a consistent association with the burden of AD, in that patients who rated their disease as moderate/severe reported similar levels of comorbidities, HRQoL impairment and HCRU as those with mild AD. However, work productivity and activity was associated with self‐rated disease severity. Moderate/severe AD patients reported significantly higher presenteeism, overall work impairment and activity impairment relative to mild AD patients. The non‐significant differences between severity levels in this study were likely due to lack of adequate power on account of small sample size. In addition, approximately 11% of the patients in the "moderate or severe" group self‐reported their disease as "severe"; thus, the burden reported for these patients reflects outcomes for patients with moderate AD much more so than for patients with severe disease. Also, there is poor concordance between self‐rated (subjective) disease severity and clinical (objective) disease severity among AD patients, which might have obscured the putative association between disease severity and burden. In support of this hypothesis, we note that the self‐rated severity distribution reported here (moderate/severe, 45.54%; mild, 54.45%) is somewhat different from that based on clinical examination of Japanese adult AD patients (23.3% and 76.7%, respectively).[9](#jde14218-bib-0009){ref-type="ref"} It is evident that further studies are required to determine the extent of the concordance (or lack thereof) between patient‐rated and physician‐rated AD severity in the real‐world clinical setting.

A particular strength of this study is that the NHWS is representative of the demographic composition of the indigenous adult population, and thus the results presented here are likely to be applicable to the wider population of Japanese AD adult patients. Adding to this, propensity‐score matching of AD patients and non‐AD controls was carried out in an effort to minimize confounding due to demographic characteristics. However, the study is limited by the fact that it evaluates patient‐reported data which are subjective and, as such, are susceptible to recall error,[43](#jde14218-bib-0043){ref-type="ref"} given that NHWS data is not independently verified against clinical records. In addition, NHWS also does not include data on key AD‐specific outcome measures, such as itch and pain. A further limitation is that the HCRU data could not be conclusively attributed to AD, because claims specifically linking resource use with these conditions are not captured by the NHWS database.

In conclusion, the results of this population‐based survey study demonstrate the substantial burden experienced by Japanese adults with AD, suggesting an unmet need for effective strategies targeting AD disease prevention and treatment. The inconsistent association of self‐rated disease severity with the burden of disease suggests a need for studies that evaluate the concordance between patient‐rated and physician‐rated AD severity in the real‐world clinical setting.
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